E
FNCH

Ergoteles’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Ergoteles’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,220
Closed -$104K – 2156
2022
Q2 		$104K Buy
1,220
+587
+93% +$50.2K ﹤0.01% 1495
2022
Q1 		$96K Sell
633
-1,496
-70% -$345K ﹤0.01% 1129
2021
Q4 		$637K Buy
+2,129
New +$816K 0.02% 553

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Ergoteles's FNCH Position: Q3 2022 in Review

Ergoteles sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q3 2022, closing a stake of 1,220 shares — an estimated $104K sold.

Ergoteles first reported a position in FNCH in Q4 2021 and held it in 3 quarters. The position peaked at $637K in Q4 2021. 43 funds tracked by Wall St. Rank hold FNCH as of Q3 2022.

  • Ergoteles reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 1,220 Finch Therapeutics Group, Inc. Common Stock shares in Q3 2022, an estimated $104K.
  • Ergoteles first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Ergoteles's Finch Therapeutics Group, Inc. Common Stock position peaked at $637K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.